Here is the response from Jim Goff, Sr. Director of Corporate Communications at PDLI to my e-mail inquiry regarding company's position on the SG Cowen analyst's comments:
"Thanks for your question in regard to PDL and the Cowen report. We continue to point out that it is premature to make judgments about Zenapax as a maintenance agent in psoriais. The Phase II study is still blinded. We do not yet know the results, nor can anyone know the results at this point in time. We expect to unblind the study and release the results via press release in the latter part of March.
Thanks again for your interest in PDL."
James Goff Sr. Director, Corporate Communications Protein Design Labs, Inc.
I would like to note that PDL responded to my inquiry in a very timely manner. I have confidence that we will bounce back from this allegation.